key: cord-0870124-ean4pm21
authors: Papamichalis, Panagiotis; Papadogoulas, Antonios; Katsiafylloudis, Periklis; Skoura, Apostolia-Lemonia; Papamichalis, Michail; Neou, Evangelia; Papadopoulos, Dimitrios; Karagiannis, Spyridon; Zafeiridis, Tilemachos; Babalis, Dimitris; Komnos, Apostolos
title: Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report
date: 2020-06-01
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.05.118
sha: ec2ee4dcce81194314a42ead2e9a0c517c5e5a58
doc_id: 870124
cord_uid: ean4pm21

In a proportion of patients Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes a multi-systematic syndrome characterized by hyperinflammation, Acute Respiratory Distress Syndrome (ARDS) and hypercoagulability. A 68-year-old man with Coronavirus Disease 2019 (COVID-19) presented in our Intensive Care Unit (ICU) with respiratory failure, Cytokine Release Syndrome (CRS) and skin ischemia – microthrombosis. Specific coagulation and inflammatory markers (D-dimer, ferritin and C-reactive protein) along with the clinical picture triggered the trial of recombinant tissue plasminogen activator (rt-PA) and Tocilizumab. This was followed by resolution of skin ischemia and CRS while respiratory parameters improved. No major complications associated with rt-PA or Tocilizumab occurred. Combination of rt-PA with targeted anti-inflammatory treatment could be a new therapeutic option for patients with COVID-19, ARDS, hyperinflammation and increased blood viscosity.

Our patient was intubated a few hours after his admission due to worsening of Another alarming observation was that of D-dimer values. Their increase was slow during patient's hospitalization but at the day of deterioration they presented a peak reaching almost double the value of the previous day, 9.8 μg/ml from 4.9 μg/ml (upper normal limit 0.5 μg/ml) (Table 1) . Ferritin (3850 ng/ml from 2820 ng/ml) and C-reactive protein (CRP) (179 mg/lt from 164 mg/lt) values showed elevation as well (Table 1) 

clinical-management-ofsevere-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-issuspected

Acute respiratory distress syndrome: the Berlin Definition

Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome

Is There a Role for Tissue Plasminogen Activator (tPA) as a Novel Treatment for Refractory COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS)?

Effective Treatment of Severe COVID-19 Patients with Tocilizumab

Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Deep vein thrombosis and pulmonary embolism: two complication of COVID-19 pneumonia?

Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia

Hematological findings and complications of COVID-19

Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation

D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis

Anticoagulant treatment is associated with decrease mortality in severe coronavisur disease 2019 patients with coagulopathy

Using heparin molecules to manage COVID-2019

Figure caption Figure 1. Patient's left hand A. Before administering Recombinant Tissue Plasminogen Activator (rt-PA)/ Tocilizumab and B. After twelve hours of continuous rt-PA infusion and two hours of Tocilizumab administration, with resolution. Patient's left foot C. Before administering rt-PA/ Tocilizumab, D. After twelve hours of continuous rt-PA